Search Result

Results for "

CRF1 antagonist

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adrenergic Receptor (1) CFTR (8) CRFR (32) Cytochrome P450 (1) Isotope-Labeled Compounds (1) Reference Standards (3)
By Research Areas:	Cancer (1) Endocrinology (11) Inflammation/Immunology (1) Metabolic Disease (7) Neurological Disease (31)
Click Chemistry:	Alkynes (3)

Inhibitors & Agonists

Peptides

Isotope-Labeled Compounds

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-106203

Crinecerfont SSR-125543	CFTR	Metabolic Disease
Crinecerfont (SSR-125543) is an orally effective corticotropin-releasing factor receptor type-1 (CRF1 receptor) antagonist. Crinecerfont blocks CRF1 receptor signaling to reduce adrenocorticotropic hormone secretion. Crinecerfont improves hypothalamic-pituitary-adrenal axis negative feedback sensitivity in chronically stressed mice. Crinecerfont can be used for the research of chronic stress conditions and classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency . Crinecerfont is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-12129

CP 154526 hydrochloride	CFTR	Neurological Disease
CP 154526 hydrochloride is a potent, brain-penetrant and selective corticotropin-releasing factor receptor 1 (CRF1) antagonist with a K_i of 2.7 nM. CP 154526 hydrochloride shows selective for CRF1 over CRF2 (K_i = >10 μM). CP 154526 hydrochloride has anxiolytic activities .

HY-12127

Pexacerfont BMS-562086	CRFR	Neurological Disease Endocrinology
Pexacerfont is a selective corticotropin-releasing factor (CRF₁) receptor antagonist with IC₅₀ of 6.1±0.6 nM for human CRF₁ receptor.

HY-14875

Verucerfont GSK561679	CRFR	Neurological Disease Endocrinology
Verucerfont is a corticotropin-releasing factor receptor 1 (CRF1) antagonist with IC₅₀s of ~6.1, >1000 and >1000?nM for CRF1, CRF2, and CRF-BP, respectively.

HY-14130

CP 376395	CRFR	Neurological Disease Endocrinology
CP 376395 is a potent, selective, and brain-penetrable Corticotropin releasing factor 1 (CRF1) receptor antagonist .

HY-106203A

Crinecerfont hydrochloride SSR-125543 hydrochloride	CFTR	Metabolic Disease
Crinecerfont (SSR-125543) hydrochloride is an orally effective corticotropin-releasing factor receptor type-1 (CRF1 receptor) antagonist. Crinecerfont hydrochloride blocks CRF1 receptor signaling to reduce adrenocorticotropic hormone secretion. Crinecerfont hydrochloride improves hypothalamic-pituitary-adrenal axis negative feedback sensitivity in chronically stressed mice. Crinecerfont hydrochloride can be used for the research of chronic stress conditions and classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency . Crinecerfont hydrochloride is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-14127

R121919 Maximum Cited Publications 7 Publications Verification NBI30775	CRFR	Neurological Disease Endocrinology
R121919 (NBI30775) is a potent and selective *CRF1R* antagonist with a K_i of 2 to 5 nM. R121919 has antidepressant and anxiolytic effects. R121919 alleviates defensive withdrawal in rats .

HY-P1294

α-Helical CRF(9-41)	CRFR	Neurological Disease
α-Helical CRF(9-41) is a competitive CRF2 receptor antagonist with K_B of ~100 nM. α-Helical CRF(9-41) is also a partial agonist of CRF1 receptor with an EC₅₀ of 140 nM .

HY-113603

Tildacerfont SPR001; LY2371712	CRFR	Metabolic Disease
Tildacerfont (SPR001; LY2371712) is an orally active, blood-brain barrier-penetrant selective corticotropin-releasing factor type 1 (CRF1) receptor antagonist. Tildacerfont selectively blocks *CRF1* receptors, thereby inhibiting the release of pituitary adrenocorticotropic hormone (ACTH). Tildacerfont can be used in research related to congenital adrenal hyperplasia .

HY-P1107

Antisauvagine-30 4 Publications Verification aSvg-30	CRFR	Neurological Disease
Antisauvagine-30 (aSvg-30) is a potent, competitive and selective CRF₂ receptor antagonist with K_d values of 1.4 nM and 153.6 nM for mouse CRF_2β and rat CRF₁ receptors, respectively .

HY-14367

Emicerfont GW876008	CRFR	Neurological Disease Endocrinology
Emicerfont is a corticotropin-releasing factor type 1 (CRF₁) receptor antagonist with an IC₅₀ of 66 nM.

HY-156522

CRF1 receptor antagonist-1	CFTR	Endocrinology
CRF1 receptor antagonist-1 (Compound 2) is a CRF1 receptor antagonist. CRF1 receptor antagonist-1 can be used for research of congenital adrenal hyperplasia (CAH) .

HY-P1294A

α-Helical CRF(9-41) TFA	CRFR	Neurological Disease
α-Helical CRF(9-41) TFA is a competitive CRF2 receptor antagonist with K_B of ~100 nM. α-Helical CRF(9-41) TFA is also a partial agonist of CRF1 receptor with an EC₅₀ of 140 nM .

HY-113603S

Tildacerfont-d8 SPR001-d₈; LY2371712-d₈	Isotope-Labeled Compounds CRFR	Cancer
Tildacerfont-d₈ (SPR001-d₈; LY2371712-d₈) is a deuterium labeled Tildacerfont (HY-113603). Tildacerfont (SPR001; LY2371712) is an orally active, blood-brain barrier-penetrant selective corticotropin-releasing factor type 1 (CRF1) receptor antagonist. Tildacerfont selectively blocks *CRF1* receptors, thereby inhibiting the release of pituitary adrenocorticotropic hormone (ACTH). Tildacerfont can be used in research related to congenital adrenal hyperplasia .

HY-12130

CP 154526	CRFR	Neurological Disease
CP 154526 is a potent, brain-penetrant and selective corticotropin-releasing factor receptor 1 (CRF1) antagonist with a K_i of 2.7 nM. CP 154526 shows selective for CRF1 over CRF2 (K_i = >10 μM). CP 154526 has anxiolytic activities .

HY-103378

NBI 35965 methanesulfonate	CRFR	Neurological Disease
NBI 35965 methanesulfonate is a selective, orally active and brain-penetrant corticotropin-releasing factor receptor 1 (CRF1) antagonist with a K_i value of 4 nM and a pK_i value of 8.5. NBI 35965 methanesulfonate does not inhibit CRF2. NBI 35965 methanesulfonate reduces CRF or stress-induced adrenocorticotropic hormone (ACTH) production in vivo with pIC₅₀ values of 7.1 and 6.9, respectively. NBI 35965 methanesulfonate shows anxiolytic effects .

HY-182645

CRF1 receptor antagonist-2	CRFR	Neurological Disease
CRF1 receptor antagonist-2 is an orally active, blood-brain barrier permeable CRF1 receptor antagonist, with an IC₅₀ of 4 nM in CHO-K1 cell membranes and an IC₅₀ of 7 nM in rat brain cell membranes. CRF1 receptor antagonist-2 exerts anxiolytic effects in swim stress-loaded rats. CRF1 receptor antagonist-2 can be used in studies related to stress-induced anxiety .

HY-14128

NBI-34041 SB-723620	CRFR	Neurological Disease
NBI-34041 (SB-723620) is a selective and orally active nonpeptide CRF1 receptor antagonist with an IC₅₀ of 58.9 nM and a K_i of 4.0 nM for human CRF1 receptor. NBI-34041 has no inhibitory effect on the CRF2 receptor. NBI-34041 can be used for depression and anxiety disorders research.

HY-14129

CP 316311	CRFR	Neurological Disease Endocrinology
CP 316311 is a potent and selective CRF1 receptor antagonist with an IC₅₀ value of 6.8 nM.

HY-103379

CP 376395 hydrochloride	CRFR	Neurological Disease Endocrinology
CP 376395 hydrochloride is a potent, selective, and brain-penetrable Corticotropin releasing factor 1 (CRF1) receptor antagonist .

HY-103376

NBI-27914 hydrochloride	CRFR	Neurological Disease
NBI-27914 (hydrochloride) is a selective Corticotropin-Releasing Factor 1 (CRF1) receptor antagonist with a K_i value of 1.7 nM .

HY-177313

AAG561 NVP-AAG 561	CFTR	Neurological Disease
AAG561 is a corticotropin-releasing factor receptor 1 (CRF1) antagonist. AAG561 can be used for the study of the underlying emotion dysregulation of a mental disease or disorder .

HY-119114

E-2508 free base	CRFR	Neurological Disease
E-2508 free base is an orally active and highly selective corticotropin-releasing factor type 1 receptor (CRF1) antagonist with anxiolytic effects (K_i=11 nM). E-2508 free base blocks CRF-induced cAMP accumulation via CRF1 receptor inhibition. E-2508 free base is promising for research of stress-related psychiatric disorders, such as anxiety and depression .

HY-123677

E2508	CRFR	Neurological Disease
E2508 is an orally active corticotropin-releasing factor 1 (CRF1) receptor antagonist with a K_i value of 11 nM for hCRF1 .

HY-12127R

Pexacerfont (Standard) BMS-562086 (Standard)	CRFR Reference Standards	Neurological Disease Endocrinology
Pexacerfont (Standard) is the analytical standard of Pexacerfont. This product is intended for research and analytical applications. Pexacerfont is a selective corticotropin-releasing factor (CRF1) receptor antagonist with IC50 of 6.1±0.6 nM for human CRF1 receptor.

HY-110310

NGD 98-2 hydrochloride	CRFR	Neurological Disease
NGD 98-2 hydrochloride is an orally active corticotropin releasing factor-1 (CRF-1) receptor antagonist

HY-114070

NGD 98-2	CRFR	Neurological Disease
NGD 98-2 is an orally active corticotropin releasing factor-1 (CRF-1) receptor antagonist

HY-110056

NBI 35965 hydrochloride	CRFR	Neurological Disease
NBI 35965 hydrochloride is a selective, orally active and brain-penetrant corticotropin-releasing factor receptor 1 (CRF1) antagonist with a K_i value of 4 nM and a pK_i value of 8.5. NBI 35965 hydrochloride does not inhibit CRF2. NBI 35965 hydrochloride reduces CRF or stress-induced adrenocorticotropic hormone (ACTH) production in vivo with pIC₅₀ values of 7.1 and 6.9, respectively. NBI 35965 hydrochloride shows anxiolytic effects .

HY-120564

BMS-763534	CRFR	Neurological Disease
BMS-763534 is a *CRF1* antagonist that inhibits neurological disorders such as depression and anxiety. .

HY-105332

CRA1000	CRFR	Neurological Disease
CRA1000 is an orally active, selective and competitive CRF1 receptor antagonist with anxiolytic- and antidepressant-like properties .

HY-12339

NVS-CRF38	CRFR	Endocrinology
NVS-CRF38 is a novel corticotropin-releasing factor receptor 1 (CRF1) antagonist with low water solubility.

HY-14225

BMS-764459	CRFR Cytochrome P450	Neurological Disease
BMS-764459 is a *CRF1* antagonist. BMS-764459 can be used for the research of neurological disorders such as depression and anxiety. BMS-764459 is also an atypical CYP1A1 inducer .

HY-106203C

Crinecerfont tosylate SSR-125543 tosylate	CFTR	Metabolic Disease
Crinecerfont (SSR-125543) tosylate is an orally effective corticotropin-releasing factor receptor type-1 (CRF1 receptor) antagonist. Crinecerfont tosylate blocks CRF1 receptor signaling to reduce adrenocorticotropic hormone secretion. Crinecerfont tosylate improves hypothalamic-pituitary-adrenal axis negative feedback sensitivity in chronically stressed mice. Crinecerfont tosylate can be used for the research of chronic stress conditions and classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency . Crinecerfont tosylate is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-107095

JNJ19567470 R317573; CRA5626; TAI041	CRFR	Neurological Disease
JNJ19567470 (R317573) is a selective, non-peptidergic **CRF type 1 receptor (CRF1)** antagonist. JNJ19567470 blocks NaLac-induced panic-like behaviour and cardiovascular responses. JNJ19567470 decreases regional glucose utilization in the amygdala, and attenuates anxiety responses .

HY-106203B

(R)-Crinecerfont (R)-SSR-125543	CFTR	Metabolic Disease
(R)-Crinecerfont is the R-enantiomer of Crinecerfont (HY-106203). Crinecerfont (SSR-125543) is an orally effective corticotropin-releasing factor receptor type-1 (CRF1 receptor) antagonist. Crinecerfont blocks CRF1 receptor signaling to reduce adrenocorticotropic hormone secretion. Crinecerfont improves hypothalamic-pituitary-adrenal axis negative feedback sensitivity in chronically stressed mice. Crinecerfont can be used for the research of chronic stress conditions and classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency . Crinecerfont is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-14132

BMS-665053	CRFR	Neurological Disease
BMS-665053 is a corticotropin-releasing factor-1 (CRF1) receptor antagonist (IC₅₀ = 1.0 nM). BMS-665053)11 is a potent inhibitor of CRF-stimulated cyclic adenosine monophosphate (cAMP) production in human Y-79 retinoblastoma cells (IC₅₀ = 4.9 nM) .

HY-118935

NGD9002 free base	Adrenergic Receptor	Inflammation/Immunology
NGD9002 free base is a new generation of selective corticotropin-releasing factor-1 (CRF-1) receptor antagonist with inhibitory activity on CRF-induced colonic function stimulation. NGD9002 free base can reduce CRF-induced fecal output response and show an inhibitory IC50 value of 4.3 mg/kg. NGD9002 free base can effectively block CRF-induced colonic secretory motility stimulation at the highest dose and reduce acute water avoidance-induced defecation. NGD9002 free base can also prevent the occurrence of pain hypersensitivity reactions to repeated colonic distension .

HY-115645

R121919 hydrochloride NBI30775 hydrochloride	CRFR	Neurological Disease Metabolic Disease
R121919 (NBI30775) hydrochloride is a potent and selective *CRF1R* antagonist with a K_i of 2 to 5 nM. R121919 hydrochloride has antidepressant and anxiolytic effects. R121919 hydrochloride alleviates defensive withdrawal in rats .

HY-106203R

Crinecerfont (Standard) SSR-125543 (Standard)	Reference Standards CFTR	Metabolic Disease
Crinecerfont (Standard) is the analytical standard of Crinecerfont (HY-106203). This product is intended for research and analytical applications. Crinecerfont (SSR-125543) is an orally effective corticotropin-releasing factor receptor type-1 (CRF1 receptor) antagonist. Crinecerfont blocks CRF1 receptor signaling to reduce adrenocorticotropic hormone secretion. Crinecerfont improves hypothalamic-pituitary-adrenal axis negative feedback sensitivity in chronically stressed mice. Crinecerfont can be used for the research of chronic stress conditions and classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Crinecerfont is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-14127R

R121919 (Standard) NBI30775 (Standard)	CRFR Reference Standards	Neurological Disease Endocrinology
R121919 (Standard) is the analytical standard of R121919. This product is intended for research and analytical applications. R121919 (NBI30775) is a potent and selective CRF1R antagonist with a Ki of 2 to 5 nM. R121919 has antidepressant and anxiolytic effects. R121919 alleviates defensive withdrawal in rats .

HY-119247

NBI 30545	CRFR	Neurological Disease
NBI 30545 is a blood-brain barrier permeable *CRF1R* antagonist with a K_i value of 3.4 nM for the human receptor. NBI 30545 inhibits CRF-stimulated intracellular cAMP accumulation and ACTH release. NBI 30545 can be used in the research of depression, anxiety disorders and stress-related diseases .

Cat. No.	Product Name	Target	Research Area

HY-P1294

α-Helical CRF(9-41)	CRFR	Neurological Disease
α-Helical CRF(9-41) is a competitive CRF2 receptor antagonist with K_B of ~100 nM. α-Helical CRF(9-41) is also a partial agonist of CRF1 receptor with an EC₅₀ of 140 nM .

HY-P1294A

α-Helical CRF(9-41) TFA	CRFR	Neurological Disease
α-Helical CRF(9-41) TFA is a competitive CRF2 receptor antagonist with K_B of ~100 nM. α-Helical CRF(9-41) TFA is also a partial agonist of CRF1 receptor with an EC₅₀ of 140 nM .

Cat. No.	Product Name	Chemical Structure

HY-113603S

Tildacerfont-d8
Tildacerfont-d₈ (SPR001-d₈; LY2371712-d₈) is a deuterium labeled Tildacerfont (HY-113603). Tildacerfont (SPR001; LY2371712) is an orally active, blood-brain barrier-penetrant selective corticotropin-releasing factor type 1 (CRF1) receptor antagonist. Tildacerfont selectively blocks *CRF1* receptors, thereby inhibiting the release of pituitary adrenocorticotropic hormone (ACTH). Tildacerfont can be used in research related to congenital adrenal hyperplasia .

Tildacerfont-d8

Tildacerfont-d₈ (SPR001-d₈; LY2371712-d₈) is a deuterium labeled Tildacerfont (HY-113603). Tildacerfont (SPR001; LY2371712) is an orally active, blood-brain barrier-penetrant selective corticotropin-releasing factor type 1 (CRF1) receptor antagonist. Tildacerfont selectively blocks CRF1 receptors, thereby inhibiting the release of pituitary adrenocorticotropic hormone (ACTH). Tildacerfont can be used in research related to congenital adrenal hyperplasia .

Cat. No.	Product Name		Classification

HY-106203

Crinecerfont SSR-125543		Alkynes
Crinecerfont (SSR-125543) is an orally effective corticotropin-releasing factor receptor type-1 (CRF1 receptor) antagonist. Crinecerfont blocks CRF1 receptor signaling to reduce adrenocorticotropic hormone secretion. Crinecerfont improves hypothalamic-pituitary-adrenal axis negative feedback sensitivity in chronically stressed mice. Crinecerfont can be used for the research of chronic stress conditions and classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency . Crinecerfont is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-106203A

Crinecerfont hydrochloride SSR-125543 hydrochloride		Alkynes
Crinecerfont (SSR-125543) hydrochloride is an orally effective corticotropin-releasing factor receptor type-1 (CRF1 receptor) antagonist. Crinecerfont hydrochloride blocks CRF1 receptor signaling to reduce adrenocorticotropic hormone secretion. Crinecerfont hydrochloride improves hypothalamic-pituitary-adrenal axis negative feedback sensitivity in chronically stressed mice. Crinecerfont hydrochloride can be used for the research of chronic stress conditions and classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency . Crinecerfont hydrochloride is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-106203B

(R)-Crinecerfont (R)-SSR-125543		Alkynes
(R)-Crinecerfont is the R-enantiomer of Crinecerfont (HY-106203). Crinecerfont (SSR-125543) is an orally effective corticotropin-releasing factor receptor type-1 (CRF1 receptor) antagonist. Crinecerfont blocks CRF1 receptor signaling to reduce adrenocorticotropic hormone secretion. Crinecerfont improves hypothalamic-pituitary-adrenal axis negative feedback sensitivity in chronically stressed mice. Crinecerfont can be used for the research of chronic stress conditions and classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency . Crinecerfont is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: